Antibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 24654-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#24654-1-AP, RRID:AB_2750601
- Product name
- SGLT2 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated SGLT2 antibody (Cat. #24654-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK/mTOR mediated autophagy pathway.
SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis.
Renal denervation ameliorates cardiac metabolic remodeling in diabetic cardiomyopathy rats by suppressing renal SGLT2 expression.
Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease.
Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
Redefining the Role of ADAM17 in Renal Proximal Tubular Cells and Its Implications in an Obese Mouse Model of Pre-Diabetes.
Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha.
Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro.
Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy.
High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells.
Yang L, Liang B, Li J, Zhang X, Chen H, Sun J, Zhang Z
Cellular signalling 2022 Feb;90:110206
Cellular signalling 2022 Feb;90:110206
SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis.
Ren D, Sun Y, Zhang D, Li D, Liu Z, Jin X, Wu H
Cancer letters 2021 Oct 28;519:277-288
Cancer letters 2021 Oct 28;519:277-288
Renal denervation ameliorates cardiac metabolic remodeling in diabetic cardiomyopathy rats by suppressing renal SGLT2 expression.
Huo JY, Jiang WY, Zhang SG, Lyu YT, Geng J, Chen M, Chen YY, Jiang ZX, Shan QJ
Laboratory investigation; a journal of technical methods and pathology 2021 Nov 13;
Laboratory investigation; a journal of technical methods and pathology 2021 Nov 13;
Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease.
Wang D, Zhang Z, Si Z, Yang Y, Li S, Xue Y
FEBS open bio 2021 May;11(5):1395-1405
FEBS open bio 2021 May;11(5):1395-1405
Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
D'Onofrio N, Sardu C, Trotta MC, Scisciola L, Turriziani F, Ferraraccio F, Panarese I, Petrella L, Fanelli M, Modugno P, Massetti M, Marfella LV, Sasso FC, Rizzo MR, Barbieri M, Furbatto F, Minicucci F, Mauro C, Federici M, Balestrieri ML, Paolisso G, Marfella R
Molecular metabolism 2021 Dec;54:101337
Molecular metabolism 2021 Dec;54:101337
Redefining the Role of ADAM17 in Renal Proximal Tubular Cells and Its Implications in an Obese Mouse Model of Pre-Diabetes.
Palau V, Villanueva S, Jarrín J, Benito D, Márquez E, Rodríguez E, Soler MJ, Oliveras A, Gimeno J, Sans L, Crespo M, Pascual J, Barrios C, Riera M
International journal of molecular sciences 2021 Dec 3;22(23)
International journal of molecular sciences 2021 Dec 3;22(23)
Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T
PloS one 2020;15(4):e0232283
PloS one 2020;15(4):e0232283
Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha.
Ndibalema AR, Kabuye D, Wen S, Li L, Li X, Fan Q
Diabetes, metabolic syndrome and obesity : targets and therapy 2020;13:1953-1967
Diabetes, metabolic syndrome and obesity : targets and therapy 2020;13:1953-1967
Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro.
Li T, Fang T, Xu L, Liu X, Li X, Xue M, Yu X, Sun B, Chen L
Frontiers in pharmacology 2020;11:622153
Frontiers in pharmacology 2020;11:622153
Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy.
Otomo H, Nara M, Kato S, Shimizu T, Suganuma Y, Sato T, Morii T, Yamada Y, Fujita H
Metabolism: clinical and experimental 2020 Dec;113:154405
Metabolism: clinical and experimental 2020 Dec;113:154405
High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells.
Hu CM, Tien SC, Hsieh PK, Jeng YM, Chang MC, Chang YT, Chen YJ, Chen YJ, Lee EYP, Lee WH
Cell metabolism 2019 Jun 4;29(6):1334-1349.e10
Cell metabolism 2019 Jun 4;29(6):1334-1349.e10
No comments: Submit comment
No validations: Submit validation data